| For: | Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2014; 20(2): 569-577 [PMID: 24574727 DOI: 10.3748/wjg.v20.i2.569] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i2/569.htm |
| Number | Citing Articles |
| 1 |
Stefan Traussnigg, Christian Kienbacher, Emina Halilbasic, Christian Rechling, Lili Kazemi-Shirazi, Harald Hofer, Petra Munda, Michael Trauner. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Digestive Diseases 2015; 33(4) doi: 10.1159/000375353
|
| 2 |
Ilias D. Vachliotis, Stergios A. Polyzos. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Current Obesity Reports 2023; 12(3) doi: 10.1007/s13679-023-00519-y
|
| 3 |
Alexandre Humbert, Rémy Lefebvre, Margaux Nawrot, Cyrielle Caussy, Jennifer Rieusset. Calcium signalling in hepatic metabolism: Health and diseases. Cell Calcium 2023; 114 doi: 10.1016/j.ceca.2023.102780
|
| 4 |
QIAN XU, JI WANG, FEIFEI CHEN, KAISU LIN, MINGAO ZHU, LEI CHEN, XIUMIN ZHOU, CHONG LI, HONG ZHU. Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms. International Journal of Molecular Medicine 2016; 38(1) doi: 10.3892/ijmm.2016.2603
|
| 5 |
Lan Yao, Jiajie Li, Xin Qin, Zhiqiang Liu, Yueying Jiang, Tianxu Zhang, Yunfeng Lin. Antifibrotic and Antioxidant Effects of a Tetrahedral Framework Nucleic Acid-Based Chlorogenic Acid Delivery System. ACS Materials Letters 2023; 5(4) doi: 10.1021/acsmaterialslett.2c00839
|
| 6 |
Feng-Ming Tian, Jian Yi, Yan Tang, Bo-Wei Chen, Hong-Ping Long, Ying-Fei Liu, Yin Ou-yang, Wen-Jiang Zhang, Rong-Mei Tang, Bai-Yan Liu. A UPLC-Q-TOF/MS and network pharmacology method to explore the mechanism of Anhua fuzhuan tea intervention in nonalcoholic fatty liver disease. Food & Function 2023; 14(8) doi: 10.1039/D2FO02774G
|
| 7 |
Simona Cernea, Avivit Cahn, Itamar Raz. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Review of Clinical Pharmacology 2017; 10(5) doi: 10.1080/17512433.2017.1300059
|
| 8 |
Mobina Mohammadi, Farshad Ghasemi, Fatemeh Ghaffari, Ali Hosseini-Sharifabad, Navid Omidifar, Javad Saffari-Chaleshtori, Maryam Nili Ahmadabadi, Amir Nili‑Ahmadabadi.
Pentoxifylline, as nonselective phosphodiesterase inhibitor, attenuate paraquat-induced hepatic damage:
in vivo
and molecular docking insights
. Drug and Chemical Toxicology 2026; doi: 10.1080/01480545.2026.2681175
|
| 9 |
Guillaume Lassailly, Robert Caiazzo, François Pattou, Philippe Mathurin. Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology 2016; 150(8) doi: 10.1053/j.gastro.2016.03.004
|
| 10 |
Ahad Eshraghian. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World Journal of Gastroenterology 2017; 23(42): 7495-7504 doi: 10.3748/wjg.v23.i42.7495
|
| 11 |
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan. Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. International Journal of Molecular Sciences 2022; 24(1) doi: 10.3390/ijms24010158
|
| 12 |
Sukhpreet Singh, Natalia A Osna, Kusum K Kharbanda. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World Journal of Gastroenterology 2017; 23(36): 6549-6570 doi: 10.3748/wjg.v23.i36.6549
|
| 13 |
Treatment of non-alcoholic fatty liver disease — Current perspectives. Indian Journal of Gastroenterology 2020; 39(1) doi: 10.1007/s12664-020-01021-2
|
| 14 |
Ken Sato, Masahiko Gosho, Takaya Yamamoto, Yuji Kobayashi, Norimitsu Ishii, Tomohiko Ohashi, Yukiomi Nakade, Kiyoaki Ito, Yoshitaka Fukuzawa, Masashi Yoneda. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Nutrition 2015; 31(7-8) doi: 10.1016/j.nut.2014.11.018
|
| 15 |
Manca Povsic, Louisa Oliver, Neha Raju Jiandani, Richard Perry, Juliana Bottomley. A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH). Pharmacology Research & Perspectives 2019; 7(3) doi: 10.1002/prp2.485
|
| 16 |
Sean W.P. Koppe. Obesity and the liver: nonalcoholic fatty liver disease. Translational Research 2014; 164(4) doi: 10.1016/j.trsl.2014.06.008
|
| 17 |
Mehmet Sayiner, Brian Lam, Pegah Golabi, Zobair M. Younossi. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818811508
|
| 18 |
P. Barton Duell, Francine K. Welty, Michael Miller, Alan Chait, Gmerice Hammond, Zahid Ahmad, David E. Cohen, Jay D. Horton, Gregg S. Pressman, Peter P. Toth. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2022; 42(6) doi: 10.1161/ATV.0000000000000153
|
| 19 |
Yoshio Sumida, Masashi Yoneda. Current and future pharmacological therapies for NAFLD/NASH. Journal of Gastroenterology 2018; 53(3) doi: 10.1007/s00535-017-1415-1
|
| 20 |
Nada Moustafa, Mona B. Abd El-latif, Alyaa Farid. Amikacin toxicity revisited: pentoxifylline offers protection in high-risk treatment scenarios. AMB Express 2025; 15(1) doi: 10.1186/s13568-025-01949-8
|
| 21 |
Pegah Golabi, Haley Bush, Zobair M. Younossi. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clinics in Liver Disease 2017; 21(4) doi: 10.1016/j.cld.2017.06.010
|
| 22 |
Rhema Khairnar, Md Asrarul Islam, Joshua Fleishman, Sunil Kumar. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sciences 2023; 312 doi: 10.1016/j.lfs.2022.121185
|
| 23 |
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. Clínica e Investigación en Arteriosclerosis (English Edition) 2017; 29(4) doi: 10.1016/j.artere.2017.07.001
|
| 24 |
Merve Cebi, Yusuf Yilmaz. Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1445634
|
| 25 |
Giovanni Musso, Franco De Michieli, Daria Bongiovanni, Renato Parente, Luciana Framarin, Nicola Leone, Mara Berrutti, Roberto Gambino, Maurizio Cassader, Solomon Cohney, Elena Paschetta. New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis–Related Kidney Disease. Clinical Gastroenterology and Hepatology 2017; 15(7) doi: 10.1016/j.cgh.2016.08.002
|
| 26 |
Emily Brown, T. Hydes, A. Hamid, D.J. Cuthbertson. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clinical Therapeutics 2021; 43(9) doi: 10.1016/j.clinthera.2021.07.013
|
| 27 |
Savinda Liyanagedera, Robert Patrick Williams, Silvio Veraldi, Valerio Nobili, Jake P. Mann. The pharmacological management of NAFLD in children and adolescents. Expert Review of Clinical Pharmacology 2017; 10(11) doi: 10.1080/17512433.2017.1365599
|
| 28 |
Xiao-Dong Zhou, Jingjing Cai, Giovanni Targher, Christopher D. Byrne, Michael D. Shapiro, Ki-Chul Sung, Virend K. Somers, C. Anwar A. Chahal, Jacob George, Li-Li Chen, Yong Zhou, Ming-Hua Zheng. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovascular Diabetology 2022; 21(1) doi: 10.1186/s12933-022-01697-0
|
| 29 |
Simona Cernea, Danusia Onișor. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World Journal of Gastroenterology 2023; 29(2): 286-309 doi: 10.3748/wjg.v29.i2.286
|
| 30 |
Shivakumar Chitturi, Geoffrey C. Farrell. Textbook of Diabetes. 2017; doi: 10.1002/9781118924853.ch51
|
| 31 |
Chra Ahmed, Haydar Al-Tukmagi, Mohammed Mohammed. CLINICAL AND BIOCHEMICAL EFFECTS OF LIFESTYLE MODIFICATION WITH PENTOXIFYLLINE, VITAMIN E IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS IN SULAIMANI. JOURNAL OF SULAIMANI MEDICAL COLLEGE 2019; 9(3) doi: 10.17656/jsmc.10214
|
| 32 |
Suhailah S. Aljameel. Pentoxifylline mitigates CCl4-induced liver damage in rats: integrated biochemical, hematological, histopathological, and correlation heatmap analysis. Brazilian Journal of Biology 2026; 86 doi: 10.1590/1519-6984.304624
|
| 33 |
Mohammed Eslam, Shiv K. Sarin, Vincent Wai-Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming-Hua Zheng, Gamal Shiha, Yusuf Yilmaz, Rino Gani, Shahinul Alam, Yock Young Dan, Jia-Horng Kao, Saeed Hamid, Ian Homer Cua, Wah-Kheong Chan, Diana Payawal, Soek-Siam Tan, Tawesak Tanwandee, Leon A. Adams, Manoj Kumar, Masao Omata, Jacob George. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International 2020; 14(6) doi: 10.1007/s12072-020-10094-2
|
| 34 |
Tomáš Fejfar, Petr Hůlek, Irma Dresslerová. Therapy of nonalcoholic steatohepatitis (NASH). Interní medicína pro praxi 2016; 18(5) doi: 10.36290/int.2016.053
|
| 35 |
Haripriya Maddur, Brent A. Neuschwander‐Tetri. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease. 2016; doi: 10.1002/9781118924938.ch20
|
| 36 |
Devaraj Ezhilarasan, Thangavelu Lakshmi, Ramoji Kosuru. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. Oxidative Medicine and Cellular Longevity 2022; 2022(1) doi: 10.1155/2022/9233650
|
| 37 |
E. B. Mitchel, J. E. Lavine. Review article: the management of paediatric nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2014; 40(10) doi: 10.1111/apt.12972
|
| 38 |
Miguel Jiménez‑Luevano, Ana Jiménez‑Partida, Miguel Jiménez‑Partida, Rodrigo Del Rio‑Hidalgo, Alejandro Bravo‑Hernández, María Villaseñor‑García, Alejandro Bravo‑Cuellar, Georgina Hernández‑Flores. Pentoxifylline in patients with COVID‑19 and with liver cirrhosis or metabolic dysfunction‑associated steatotic liver disease: Emerging insights. Biomedical Reports 2026; 24(6) doi: 10.3892/br.2026.2150
|
| 39 |
Inês Domingues, Isabelle A. Leclercq, Ana Beloqui. Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery. Journal of Controlled Release 2023; 363 doi: 10.1016/j.jconrel.2023.09.040
|
| 40 |
Shahinul Alam, SKM Nazmul Hasan, Golam Mustafa, Mahabubul Alam, Mohammad Kamal, Nooruddin Ahmad. Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial. Journal of Translational Internal Medicine 2017; 5(3) doi: 10.1515/jtim-2017-0021
|
| 41 |
Milica Culafic, Sandra Vezmar Kovacevic, Violeta Dopsaj, Branislav Oluic, Nemanja Bidzic, Branislava Miljkovic, Djordje Culafic. Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis. Journal of Medical Biochemistry 2019; 0(0) doi: 10.2478/jomb-2019-0043
|
| 42 |
Tao Zhang, Yingli Nie, Jiliang Wang. The emerging significance of mitochondrial targeted strategies in NAFLD treatment. Life Sciences 2023; 329 doi: 10.1016/j.lfs.2023.121943
|
| 43 |
Diana V Avila, David F Barker, JingWen Zhang, Craig J McClain, Shirish Barve, Leila Gobejishvili. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol‐induced steatosis. The Journal of Pathology 2016; 240(1) doi: 10.1002/path.4760
|
| 44 |
Nadieh Baniasadi, Faranak Salajegheh, Abbas Pardakhty, Seyed Mehdi Seyedmirzaee, Mohammad Mahdi Hayatbakhsh, Amin Reza Nikpoor, Mojgan Mohammadi. Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. Hepatitis Monthly 2015; 15(11) doi: 10.5812/hepatmon.32418
|
| 45 |
Sijia Lu, Yibing Wang, Junli Liu. Tumor necrosis factor-α signaling in nonalcoholic steatohepatitis and targeted therapies. Journal of Genetics and Genomics 2022; 49(4) doi: 10.1016/j.jgg.2021.09.009
|
| 46 |
Sebastian Larion, Caleb A. Padgett, Joshua T. Butcher, James D. Mintz, David J. Fulton, David W. Stepp. The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm. American Journal of Physiology-Gastrointestinal and Liver Physiology 2022; 323(4) doi: 10.1152/ajpgi.00130.2022
|
| 47 |
Lawrence Serfaty. Traitements pharmacologiques de la NASH. La Presse Médicale 2019; 48(12) doi: 10.1016/j.lpm.2019.09.015
|
| 48 |
|
| 49 |
Wanying Geng, Wanying Liao, Xinyuan Cao, Yingyun Yang. Therapeutic Targets and Approaches to Manage Inflammation of NAFLD. Biomedicines 2025; 13(2) doi: 10.3390/biomedicines13020393
|
| 50 |
Neel Malhotra, Melanie D Beaton. Management of non-alcoholic fatty liver disease in 2015. World Journal of Hepatology 2015; 7(30): 2962-2967 doi: 10.4254/wjh.v7.i30.2962
|
| 51 |
Xiao-Dong Zhou, Giovanni Targher, Christopher D. Byrne, Virend Somers, Seung Up Kim, C. Anwar A. Chahal, Vincent Wai-Sun Wong, Jingjing Cai, Michael D. Shapiro, Mohammed Eslam, Philippe Gabriel Steg, Ki-Chul Sung, Anoop Misra, Jian-Jun Li, Carlos Brotons, Yuli Huang, George V. Papatheodoridis, Aijun Sun, Yusuf Yilmaz, Wah Kheong Chan, Hui Huang, Nahum Méndez-Sánchez, Saleh A. Alqahtani, Helena Cortez-Pinto, Gregory Y. H. Lip, Robert J. de Knegt, Ponsiano Ocama, Manuel Romero-Gomez, Marat Fudim, Giada Sebastiani, Jang Won Son, John D. Ryan, Ignatios Ikonomidis, Sombat Treeprasertsuk, Daniele Pastori, Monica Lupsor-Platon, Herbert Tilg, Hasmik Ghazinyan, Jerome Boursier, Masahide Hamaguchi, Mindie H. Nguyen, Jian-Gao Fan, George Boon-Bee Goh, Mamun Al Mahtab, Saeed Hamid, Nilanka Perera, Jacob George, Ming-Hua Zheng. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatology International 2023; 17(4) doi: 10.1007/s12072-023-10543-8
|
| 52 |
Maryam Mahjoubin-Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen L. Atkin, Christos S. Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular Metabolism 2021; 50 doi: 10.1016/j.molmet.2020.101049
|
| 53 |
Jonathan Merola, AnnMarie Liapakis, David C. Mulligan, Peter S. Yoo. Non‐alcoholic fatty liver disease following liver transplantation: a clinical review. Clinical Transplantation 2015; 29(9) doi: 10.1111/ctr.12585
|
| 54 |
Jonathan M. Hazlehurst, Jeremy W. Tomlinson. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease. 2016; doi: 10.1002/9781118924938.ch24
|
| 55 |
David Højland Ipsen, Josephine Skat‐Rørdam, Marianne Svenningsen, Mia Andersen, Markus Latta, Lene Elisabeth Buelund, Kristine Lintrup, René Skaarup, Jens Lykkesfeldt, Pernille Tveden‐Nyborg. The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non‐alcoholic steatohepatitis. Basic & Clinical Pharmacology & Toxicology 2021; 128(4) doi: 10.1111/bcpt.13549
|
| 56 |
Gehad Nasr, Doaa Mohamed Elroby Ali, Michael A. Fawzy, Fares E.M. Ali, Moustafa Fathy. Combined quercetin with phosphodiesterase inhibitors; sildenafil and pentoxifylline alleviated CCl4-induced chronic hepatic fibrosis: Role of redox-sensitive pathways. Food and Chemical Toxicology 2025; 201 doi: 10.1016/j.fct.2025.115442
|
| 57 |
Mahmoud Samy Abdallah, Ahmed Hossam Eldeen, Sally Said Tantawy, Tarek Mohamed Mostafa. The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial. European Journal of Pharmacology 2021; 906 doi: 10.1016/j.ejphar.2021.174295
|
| 58 |
Stephen A. Harrison, Mark M. Pence, Amy N. Stratton, Dawn M. Torres. Zakim and Boyer's Hepatology. 2018; doi: 10.1016/B978-0-323-37591-7.00027-6
|
| 59 |
Jorge Gutiérrez-Cuevas, Silvia Lucano-Landeros, Daniel López-Cifuentes, Arturo Santos, Juan Armendariz-Borunda. Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers 2022; 15(1) doi: 10.3390/cancers15010023
|
| 60 |
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico. Clínica e Investigación en Arteriosclerosis 2017; 29(4) doi: 10.1016/j.arteri.2016.06.002
|
| 61 |
Virender Kumar, Xiaofei Xin, Jingyi Ma, Chalet Tan, Natalia Osna, Ram I. Mahato. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Advanced Drug Delivery Reviews 2021; 176 doi: 10.1016/j.addr.2021.113888
|
| 62 |
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, Antonios Chatzigeorgiou. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease. Hormones 2024; 23(4) doi: 10.1007/s42000-024-00588-1
|
| 63 |
Parisa Shabani, H Naeimi Khaledi, Maani Beigy, Solaleh Emamgholipour, Eskandar Parvaz, Hossein Poustchi, Mahmood Doosti, Manlio Vinciguerra. Circulating Level of CTRP1 in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Is It through Insulin Resistance?. PLOS ONE 2015; 10(3) doi: 10.1371/journal.pone.0118650
|
| 64 |
Ratree Sawangjit, Bunchai Chongmelaxme, Pochamana Phisalprapa, Surasak Saokaew, Ammarin Thakkinstian, Kris V. Kowdley, Nathorn Chaiyakunapruk. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD). Medicine 2016; 95(32) doi: 10.1097/MD.0000000000004529
|
| 65 |
Robert Gish, Jian-Gao Fan, Zahra Dossaji, Jeanne Fichez, Tooba Laeeq, Magnus Chun, Jerome Boursier. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. Hepatology International 2024; 18(S2) doi: 10.1007/s12072-024-10698-y
|
| 66 |
Jia Wang, Yanfei Hao, Xiao Jin, Xiaoyue Li, Yi Liu, Li Zhang, Jing Wang, Mingxin Hu, Shimin Wang. Health Effects of Probiotics on Nonalcoholic Fatty Liver in the Life Cycle Based on Data Analysis. Computational and Mathematical Methods in Medicine 2022; 2022 doi: 10.1155/2022/2123162
|
| 67 |
Ana M. Ijacu, Laura G. Gagiu , Iulia M. Staicu , Corina Zugravu , Ciprian Constantin . Non-alcoholic Steatohepatitis Diagnosis and Treatment – Current Concepts. Romanian Journal of Military Medicine 2025; 128(1) doi: 10.55453/rjmm.2025.128.1.1
|
| 68 |
Juan P Arab, Roberto Candia, Arnoldo Riquelme, Marco Arrese, M Carolina Cuellar, Jorge Contreras, Edgar Sanhueza, Javier Brahm, Francisco Fuster, Alejandro Soza, Jaime Poniachik, Juan P Arancibia, Cristián Muñoz, Rodrigo Zapata. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World Journal of Gastroenterology 2014; 20(34): 12182-12201 doi: 10.3748/wjg.v20.i34.12182
|
| 69 |
Seung Jin Han, Hae Jin Kim, Dae Jung Kim, Seung Soo Sheen, Choon Hee Chung, Chul Woo Ahn, Se Hwa Kim, Yong-Wook Cho, Seok Won Park, Soo-Kyung Kim, Chul Sik Kim, Kyung Wook Kim, Kwan Woo Lee. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetology & Metabolic Syndrome 2015; 7(1) doi: 10.1186/s13098-015-0060-1
|
| 70 |
Nevien Hendawy. Pentoxifylline attenuates cytokine stress and Fas system in syngeneic liver proteins induced experimental autoimmune hepatitis. Biomedicine & Pharmacotherapy 2017; 92 doi: 10.1016/j.biopha.2017.05.084
|
| 71 |
Elham Najafi, Motahareh Ahmadi, Mostafa Mohammadi, Mohammad-Taghi Beigmohammadi, Zinat Heidary, Alireza Vatanara, Hossein Khalili. Topical pentoxifylline for pressure ulcer treatment: a randomised, double-blind, placebo-controlled clinical trial. Journal of Wound Care 2018; 27(8) doi: 10.12968/jowc.2018.27.8.495
|
| 72 |
Marta Alonso-Peña, Maria Del Barrio, Ana Peleteiro-Vigil, Carolina Jimenez-Gonzalez, Alvaro Santos-Laso, Maria Teresa Arias-Loste, Paula Iruzubieta, Javier Crespo. Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key. International Journal of Molecular Sciences 2023; 24(13) doi: 10.3390/ijms241310718
|
| 73 |
Alice Addis, Victoria Savage. Management of hepatopathy in horses. UK-Vet Equine 2024; 8(2) doi: 10.12968/ukve.2024.8.2.85
|
| 74 |
Da Zhou, Jiangao Fan. Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction. Chinese Medical Journal 2024; 137(22) doi: 10.1097/CM9.0000000000003355
|
| 75 |
Monika Bhardwaj, Papiya Mitra Mazumder. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus. Naunyn-Schmiedeberg's Archives of Pharmacology 2024; 397(11) doi: 10.1007/s00210-024-03204-6
|
| 76 |
Omima S. Mohammed, Hany G. Attia, Bassim M. S. A. Mohamed, Marawan A. Elbaset, Hany M. Fayed. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. Journal of Pharmacy & Pharmaceutical Sciences 2023; 26 doi: 10.3389/jpps.2023.11808
|
| 77 |
Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar. A Comprehensive Systematic Review on Therapeutic Discovery of NAFLD Drugs. Research Journal of Pharmacy and Technology 2025; doi: 10.52711/0974-360X.2025.00655
|
| 78 |
Nadieh Baniasadi, Faranak Salajegheh, Abbas Pardakhty, Seyed Mehdi Seyedmirzaee, Mohammad Mahdi Hayatbakhsh, Amin Reza Nikpoor, Mojgan Mohammadi. Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. Hepatitis Monthly 2015; 15(11) doi: 10.5812/hepatmon.33462
|
| 79 |
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8) doi: 10.1016/j.metabol.2016.05.003
|
| 80 |
Yasaman Ramazani, Noël Knops, Mohamed A. Elmonem, Tri Q. Nguyen, Fanny Oliveira Arcolino, Lambert van den Heuvel, Elena Levtchenko, Dirk Kuypers, Roel Goldschmeding. Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biology 2018; doi: 10.1016/j.matbio.2018.03.007
|
| 81 |
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023; 59(10) doi: 10.3390/medicina59101789
|
| 82 |
Yoshio Sumida, Toshihide Shima, Yasuhide Mitsumoto, Takafumi Katayama, Atsushi Umemura, Kanji Yamaguchi, Yoshito Itoh, Masashi Yoneda, Takeshi Okanoue. Epidemiology, Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. International Journal of Molecular Sciences 2020; 21(12) doi: 10.3390/ijms21124337
|
| 83 |
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis. Diabetes, Metabolic Syndrome and Obesity 2024; doi: 10.2147/DMSO.S448476
|
| 84 |
Evaluation of the Possible Protective Effect of Pentoxifylline Against Carbamazepine-Induced Hepatotoxicity in Rat Model. Al Mustansiriyah Journal of Pharmaceutical Sciences 2025; 25(4) doi: 10.32947/ajps.v25i4.1216
|
| 85 |
Yaron Rotman, Arun J Sanyal. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017; 66(1) doi: 10.1136/gutjnl-2016-312431
|
| 86 |
Kelly Torosian, Esha Lal, Arthur Kavanaugh, Rohit Loomba, Veeral Ajmera, Monica Guma. Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Seminars in Arthritis and Rheumatism 2023; 59 doi: 10.1016/j.semarthrit.2023.152165
|
| 87 |
Vikas Uppal, Sana Mansoor, Katryn N. Furuya. Pediatric Non-alcoholic Fatty Liver Disease. Current Gastroenterology Reports 2016; 18(5) doi: 10.1007/s11894-016-0498-9
|
| 88 |
Sarah E. Fleet, Jay H. Lefkowitch, Joel E. Lavine. Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology Clinics of North America 2017; 46(2) doi: 10.1016/j.gtc.2017.01.002
|
| 89 |
Ricardo Amorim, Pedro Soares, Daniel Chavarria, Sofia Benfeito, Fernando Cagide, José Teixeira, Paulo J. Oliveira, Fernanda Borges. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities. European Journal of Medicinal Chemistry 2024; 277 doi: 10.1016/j.ejmech.2024.116723
|